A Deeper Investigation of Drug Degradation Mixtures Using a Combination of MS and NMR Data: Application to Indapamide.
NMR
NUS
PLS
UPLC-UV-HDMSE
forced degradations
indapamide
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
07 May 2019
07 May 2019
Historique:
received:
18
01
2019
revised:
30
04
2019
accepted:
05
05
2019
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
29
8
2019
Statut:
epublish
Résumé
A global approach that is based on a combination of mass spectrometry (MS) and nuclear magnetic resonance (NMR) data has been developed for a complete and rapid understanding of drug degradation mixtures. We proposed a workflow based on a sample preparation protocol that is compatible to MS and NMR, the selection of the most appropriate experiments for each technique, and the implementation of prediction software and multivariable analysis method for a better interpretation and correlation of MS and NMR spectra. We have demonstrated the efficient quantification of the remaining active pharmaceutical ingredient (API). The unambiguous characterization of degradation products (DPs) was reached while using the potential of ion mobility-mass spectrometry (IM-MS) for fragment ions filtering (HDMS
Identifiants
pubmed: 31067700
pii: molecules24091764
doi: 10.3390/molecules24091764
pmc: PMC6539681
pii:
doi:
Substances chimiques
Indapamide
F089I0511L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Angew Chem Int Ed Engl. 2003 Aug 25;42(33):3938-41
pubmed: 12949874
Phytochem Anal. 2010 Jan-Feb;21(1):4-13
pubmed: 19904733
Nat Chem. 2014 Apr;6(4):281-94
pubmed: 24651194
J Pharm Biomed Anal. 2014 Dec;101:102-22
pubmed: 24853620
Anal Chem. 2014 Dec 2;86(23):11474-80
pubmed: 25348289
J Pharm Biomed Anal. 2015;111:190-203
pubmed: 25890215
Magn Reson Chem. 2015 Nov;53(11):913-20
pubmed: 26053155
Curr Opin Biotechnol. 2017 Feb;43:17-24
pubmed: 27552705
Metabolomics. 2017;13(4):36
pubmed: 28261014
Mass Spectrom Rev. 2018 Jul;37(4):513-532
pubmed: 28436590
J Pharm Biomed Anal. 2018 Jan 5;147:580-589
pubmed: 28583765
J Pharm Biomed Anal. 2017 Sep 5;143:141-146
pubmed: 28595107
Mass Spectrom Rev. 2018 Sep;37(5):607-629
pubmed: 29120505
Curr Opin Chem Biol. 2018 Feb;42:147-159
pubmed: 29306688
Metabolites. 2018 Jan 17;8(1):null
pubmed: 29342073
J Pharm Anal. 2014 Jun;4(3):159-165
pubmed: 29403878
J Pharm Biomed Anal. 2018 Oct 25;160:89-98
pubmed: 30075398